天津中医药2025，Vol.42Issue(3)：315-321,7.DOI:10.11656/j.issn.1672-1519.2025.03.09
丹红注射液治疗急性脑梗死系统评价再评价
Reevaluation of systematic reviews on Danhong Injection in the treatment of acute cerebral infarction
摘要
Abstract
[Objective]To evaluate the systematic review/Meta methodology quality of randomized controlled trials of Danhong Injection in the treatment of acute cerebral infarction,and to ebaluate the methodological quality and the status of clinical evidence.[Methods]Systematic review of randomized controlled trials of Danhong Injection in the treatment of acute cerebral infarction were searched in The Chinese Fulltext Journal Database(CNKI),Wanfang Data,SinoMed,PubMed,EMbase and the Cochrane Library databases from inception to June 2023.The AMSTAR2 scale was used to evaluate the methodological quality of the included systematic reviews,and the results of the systematic reviews were summarized.[Results]Fourteen systematic reviews of Danhong Injection in the treatment of acute cerebral infarction were included.The results showed that Danhong Injection could improve the clinical effective rate,neurological deficit score and activities of daily living in patients with acute cerebral infarction,and no serious adverse reactions were reported.It was found that the quality of systematic reviews of the included randomized controlled trials was extremely low,all systematic reviews did not report key item 2 and key item 7,and the bias risk assessment method used in the included studies was unreasonable.All systematic reviews failed to report non-critical items 3,10,and 16,namely to explain the choice of study design,to report information on the funding of the systematic review,and to report sources of potential conflicts of interest.[Conclusion]The published systematic evaluation results of Danhong Injection in the treatment of acute cerebral infarction showed that Danhong Injection alone or in combination can improve the clinical effective rate,improve the neurological deficit function score and daily living ability of patients with acute cerebral infarction,and has good safety.However,due to the low overall quality of the original study and systematic review,the reliability of the results is affected,and high-quality clinical evidence is needed to support clinical decision-making.关键词
丹红注射液/急性脑梗死/系统评价/再评价/循证医学Key words
Danhong Injection/acute cerebral infarction/systematic review/overview of systematic review/evidence based medicine分类
临床医学引用本文复制引用
朱征,王可仪,赵霞,张雅姿,陈波,杨丰文..丹红注射液治疗急性脑梗死系统评价再评价[J].天津中医药,2025,42(3):315-321,7.基金项目
2022年度天津市教委科研计划项目(2022KJ153). （2022KJ153）
